SCHEMBL2870816

SCHEMBL2870816

COC(=O)c1sc(-c2ccccc2)cc1N(CC1CCCN(C(=O)OCc2ccccc2)C1)C(=O)C1CCC(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ ACKR3 P25106 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ BCL9 O00512 4/20 0.37
▸ CTNNB1 P35222 4/20 0.37
▸ CHRNB2 P17787 3/20 0.37
▸ CHRNA4 P43681 3/20 0.37
▸ LCK P06239 1/20 0.36
▸ CHRNB4 P30926 2/20 0.36
▸ CHRNA3 P32297 2/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14030802 0.93 ACKR3 (0.38) HTTACKR3NPC1RAB9ASMN1; SMN2
SCHEMBL2879579 0.91 SMN1; SMN2 (0.44) HTTKDM4EATMNPC1RAB9A
SCHEMBL2876967 0.88 KDM4E (0.46) HTTKDM4EATMCHRNB2CHRNA4
SCHEMBL6426855 0.84 SMN1; SMN2 (0.45) HTTNPC1RAB9ASMN1; SMN2
SCHEMBL14030873 0.83 SMN1; SMN2 (0.43) HTTNPC1RAB9ASMN1; SMN2
SCHEMBL2746312 0.82 SMN1; SMN2 (0.45) HTTKDM4EATMNPC1RAB9A
SCHEMBL14136980 0.80 SMN1; SMN2 (0.44) HTTKDM4EATMNPC1RAB9A
SCHEMBL2877042 0.80 NR1I2 (0.41) HTTKDM4EATMCHRNB2CHRNA4
SCHEMBL12464666 0.80 SMN1; SMN2 (0.45) HTTNPC1RAB9ASMN1; SMN2
SCHEMBL2877282 0.78 ACKR3 (0.49) HTTKDM4EATMACKR3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569929-B9 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VIROCHEM PHARMA INC (CA) 2011-09-14 — — EP claimed
EP-1569929-B1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VIROCHEM PHARMA INC (CA) 2010-05-05 — — EP claimed
Send feedback